Breast Carcinogenesis—Can the Examination of Ductal Fluid Enhance Our Understanding?

Kimberly Baltzell

Suzanne E. Eder

Margaret Wrensch

ONF 2005, 32(1), 33-39. DOI: 10.1188/05.ONF.33-39

Purpose/Objectives: To explore current breast carcinogenesis theories and the possibility of examining breast epithelial cells to confirm steps in the carcinogenic process and the relationship between intraductal sampling techniques and their role in enhanced risk prediction.

Jump to a section

    References

    Allred, D.C., Mohsin, S.K., & Fuqua, S.A. (2001). Histological and biological evolution of human premalignant breast disease. Endocrine Related Cancer, 8, 47-61.

    Ariga, R., Bloom, K., Reddy, V.B., Kluskens, L., Francescatti, D., Dowlat, K., et al. (2002). Fine-needle aspiration of clinically suspicious palpable breast masses with histopathologic correlation. American Journal of Surgery, 184, 410-413.

    Barrows, G.H., Anderson, T.J., Lamb, J.L., & Dixon, J.M. (1986). Fine-needle aspiration of breast cancer. Relationship of clinical factors to cytology results in 689 primary malignancies. Cancer, 58, 1493-1498.

    Briand, P., & Lykkesfeldt, A.E. (2001). An in vitro model of human breast carcinogenesis: Epigenetic aspects. Breast Cancer Research and Treatment, 65, 179-187.

    Claus, E., Risch, N., & Thompson, W. (1993). The calculation of breast cancer risk for women with a first degree family history of ovarian cancer. Breast Cancer Research and Treatment, 28, 115-120.

    Dickson, R., & Lippmann, M. (2000). Oncogenes and suppressor genes. In J. Harris, M. Lippman, M. Morrow, & C. Osborne (Eds.), Diseases of the breast (2nd ed., p. 281). Philadelphia: Lippincott.

    Domchek, S.M. (2002). The utility of ductal lavage in breast cancer detection and risk assessment. Breast Cancer Research, 4(2), 51-53.

    Dooley, W.C., Ljung, B.M., Veronesi, U., Cazzaniga, M., Elledge, R.M., O'Shaughnessy, J.A., et al. (2001). Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. Journal of the National Cancer Institute, 93, 1624-1632.

    Esserman, L., Adduci, K., Chew, K., & Ljung, B. (2003, March). Does ductal lavage hold risk assessment and diagnostic potential? The Third International Santa Barbara Symposium: The Intraductal Approach to Breast Cancer, Santa Barbara, CA.

    Euhus, D.M., Cler, L., Shivapurkar, N., Milchgrub, S., Peters, G.N., Leitch, A.M., et al. (2002). Loss of heterozygosity in benign breast epithelium in relation to breast cancer risk. Journal of the National Cancer Institute, 94, 858-860.

    Euhus, D.M., Smith, K.C., Robinson, L., Stucky, A., Olopade, O.I., Cummings, S., et al. (2002). Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. Journal of the National Cancer Institute, 94, 844-851.

    Fabian, C.J., & Kimler, B.F. (2001). Breast cancer risk prediction: Should nipple aspiration fluid cytology be incorporated into clinical practice? Journal of the National Cancer Institute, 93, 1762-1763.

    Fabian, C.J., Kimler, B.F., Zalles, C.M., Klemp, J.R., Kamel, S., Zeiger, S., et al. (2000). Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. Journal of the National Cancer Institute, 92, 1217-1227.

    Gail, M.H., Brinton, L.A., Byar, D.P., Corle, D.K., Green, S.B., Schairer, C., et al. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute, 81, 1879-1886.

    Hahn, W.C., & Weinberg, R.A. (2002). Rules for making human tumor cells. New England Journal of Medicine, 347, 1593-1603.

    Henderson, B., Pike, M., Bernstein, L., & Ross, R. (1996). Breast cancer. In D.F. Schottenfeld & J.F. Fraumeni, Jr. (Eds.), Cancer epidemiology and prevention (pp. 1002-1039). New York: Oxford.

    Hughes, L., Mansel, R., & Webster, D. (Eds.). (2000). Benign disorders and diseases of the breast. London: Saunders.

    Kelly, P. (2000). Assess your true risk of breast cancer. New York: Henry Holt.

    King, E.B., Chew, K.L., Petrakis, N.L., & Ernster, V.L. (1983). Nipple aspirate cytology for the study of breast cancer precursors. Journal of the National Cancer Institute, 71, 1115-1121.

    Knudson, A.G., Jr. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the United States of America, 68, 820-823.

    Krishnamurthy, S., Sneige, N., Thompson, P.A., Marcy, S.M., Singletary, S.E., Cristofanilli, M., et al. (2003). Nipple aspirate fluid cytology in breast carcinoma. Cancer, 99, 97-104.

    Last, J. (2001). A dictionary of epidemiology. New York: Oxford.

    Martin, G. (1996). Normal cells and cancer cells. In J.W. Bishop (Ed.), Molecular oncology (pp. 13-40). New York: Scientific American.

    Masood, S. (1999). Diagnostic terminology in fine-needle aspiration biopsy of the breast: Redefining the term "atypia." Cancer, 87, 1-4.

    McCarty, K., & Tucker, J. (1992). Breast histology for pathologists. New York: Raven Press.

    Miller, D., Bates, P., & Nabell, L. (2002). Molecular biology of breast cancer. In W. Donegan & J. Spratt (Eds.), Cancer of the breast (5th ed., pp. 181-198). Philadelphia: Saunders.

    O'Shaughnessy, J.A. (2000). Treating breast precancer. Clinical Breast Cancer, 1(1, Suppl. 1), S74-S79.

    Page, D.L., & Rogers, L.W. (1992). Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. Human Pathology, 23, 1095-1097.

    Papanicolaou, G.N., Holmquist, D.G., Bader, G.M., & Falk, E.A. (1958). Exfoliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer, 11, 377-409.

    Prehn, R.T. (1994). Cancers beget mutations versus mutations beget cancers. Cancer Research, 54, 5296-5300.

    Rose, D.P., Lahti, H., Laakso, K., Kettunen, K., & Wynder, E.L. (1986). Serum and breast duct fluid prolactin and estrogen levels in healthy Finnish and American women and patients with fibrocystic disease. Cancer, 57, 1550-1554.

    Rosen, P. (2001). Rosen's breast pathology (2nd ed.). Philadelphia: Lippincott.

    Sauter, E.R., Ross, E., Daly, M., Klein-Szanto, A., Engstrom, P.F., Sorling, A., et al. (1997). Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk. British Journal of Cancer, 76, 494-501.

    Shao, Z.M., & Nguyen, M. (2001). Nipple aspiration in diagnosis of breast cancer. Seminars in Surgical Oncology, 20, 175-180.

    Studzinski, G., & Harrison, L. (2002). Genetic basis for the emergence and progression of breast cancer. In W. Donegan & J. Spratt (Eds.), Cancer of the breast (5th ed., pp. 169-180). London: Saunders.

    Tannock, I., & Hill, R. (1998). The basic science of oncology. New York: McGraw-Hill.

    Vineis, P. (2003). Cancer as an evolutionary process at the cell level: An epidemiological perspective. Carcinogenesis, 24, 1-6.

    Willet, W., Rockhill, B., Hankinson, S., Hunter, D., & Colditz, G. (2000). Epidemiology and assessing and managing risk. In J. Harris, M. Lippman, M. Morrow, & C. Osborne (Eds.), Diseases of the breast (2nd ed., pp. 175-219). Philadelphia: Lippincott.

    Wrensch, M.R., Petrakis, N.L., Gruenke, L.D., Ernster, V.L., Miike, R., King, E.B., et al. (1990). Factors associated with obtaining nipple aspirate fluid: Analysis of 1428 women and literature review. Breast Cancer Research and Treatment, 15, 39-51.

    Wrensch, M.R., Petrakis, N.L., King, E.B., Miike, R., Mason, L., Chew, K.L., et al. (1992). Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. American Journal of Epidemiology, 135, 130-141.

    Wrensch, M.R., Petrakis, N.L., Miike, R., King, E.B., Chew, K., Neuhaus, J., et al. (2001). Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. Journal of the National Cancer Institute, 93, 1791-1798.

    Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C., & Wahl, G.M. (1992). Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell, 70, 937-948.